|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Papaetis GS, Roussos C and Syrigos KN:
Targeted therapies for non-small cell lung cancer. Curr Pharm Des.
13:2810–2831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan WD, Zhang XQ, Guo HL, Zeng WW, Zhang
N, Wan QQ, Xie WY, Cao J and Xu CH: Bioinformatics analysis reveals
connection of squamous cell carcinoma and adenocarcinoma of the
lung. Asian Pac J Cancer Prev. 13:1477–1482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Younes RN, Pereira JR, Fares AL and Gross
JL: Chemotherapy beyond first-line in stage IV metastatic non-small
cell lung cancer. Rev Assoc Med Bras (1992). 57:686–691. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gainor JF and Shaw AT: Novel targets in
non-small cell lung cancer: ROS1 and RET fusions. Oncologist.
18:865–875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dimartino D, Colantoni A, Ballarino M,
Martone J, Mariani D, Danner J, Bruckmann A, Meister G, Morlando M
and Bozzoni I: The long non-coding RNA lnc-31 interacts with Rock1
mRNA and mediates its YB-1-dependent translation. Cell Rep.
23:733–740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi X, Liu Z, Liu Z, Feng X, Hua F, Hu X,
Wang B, Lu K and Nie F: Long noncoding RNA PCAT6 functions as an
oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell
lung cancer. EBioMedicine. 37:177–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu Q, Shan S, Li Y, Zhu D, Jin W and Ren
T: Long noncoding RNA SNHG1 promotes non-small cell lung cancer
progression by up-regulating MTDH via sponging miR-145-5p. FASEB J.
32:3957–3967. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan J and Yang L: Long noncoding RNA
VPS9D1-AS1 overexpression predicts a poor prognosis in non-small
cell lung cancer. Biomed Pharmacother. 106:1600–1606. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Varon M, Levy T, Mazor G, Ben David H,
Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, et
al: The long noncoding RNA TP73-AS1 promotes tumorigenicity of
medulloblastoma cells. Int J Cancer. 145:3402–3413. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu G, Zhao X, Zhou J, Cheng X, Ye Z and
Ji Z: lncRNA TP73-AS1 promotes cell proliferation and inhibits cell
apoptosis in clear cell renal cell carcinoma through repressing
KISS1 expression and inactivation of PI3K/Akt/mTOR signaling
pathway. Cell Physiol Biochem. 48:371–384. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
16
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li
Y, Li Z, Ng SS, Sung JJ, et al: miR-34a-5p suppresses colorectal
cancer metastasis and predicts recurrence in patients with stage
II/III colorectal cancer. Oncogene. 34:4142–4152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhong Z, Zhou F, Wang D, Wu M, Zhou W, Zou
Y, Li J, Wu L and Yin X: Expression of KLF9 in pancreatic cancer
and its effects on the invasion, migration, apoptosis, cell cycle
distribution, and proliferation of pancreatic cancer cell lines.
Oncol Rep. 40:3852–3860. 2018.PubMed/NCBI
|
|
19
|
Sun Z, Zhang B and Cui T: Long non-coding
RNA XIST exerts oncogenic functions in pancreatic cancer via
miR-34a-5p. Oncol Rep. 39:1591–1600. 2018.PubMed/NCBI
|
|
20
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masuda Y, Takahashi H, Sato S,
Tomomori-Sato C, Saraf A, Washburn MP, Florens L, Conaway RC,
Conaway JW and Hatakeyama S: TRIM29 regulates the assembly of DNA
repair proteins into damaged chromatin. Nat Commun. 6:72992015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Napolitano LM and Meroni G: TRIM family:
Pleiotropy and diversification through homomultimer and
heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ai L, Kim WJ, Alpay M, Tang M, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM and Brown
KD: TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
|
|
25
|
Xu J, Li Z, Su Q, Zhao J and Ma J: TRIM29
promotes progression of thyroid carcinoma via activating P13K/AKT
signaling pathway. Oncol Rep. 37:1555–1564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan ST, Liu SY and Wu B: TRIM29
overexpression promotes proliferation and survival of bladder
cancer cells through NF-κB signaling. Cancer Res Treat.
48:1302–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Balata H, Fong KM, Hendriks LE, Lam S,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in thoracic oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu D, Zhou J, Liu Y, Du L, Zheng Z and
Qian X: lncRNA TP73-AS1 is upregulated in non-small cell lung
cancer and predicts poor survival. Gene. 710:98–102. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Fang F and He X: Long noncoding
RNA TP73-AS1 promotes non-small cell lung cancer progression by
competitively sponging miR-449a/EZH2. Biomed Pharmacother.
104:705–711. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mazor G, Levin L, Picard D, Ahmadov U,
Carén H, Borkhardt A, Reifenberger G, Leprivier G, Remke M and
Rotblat B: The lncRNA TP73-AS1 is linked to aggressiveness in
glioblastoma and promotes temozolomide resistance in glioblastoma
cancer stem cells. Cell Death Dis. 10:2462019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen B, Shen Z, Wu D, Xie X, Xu X, Lv L,
Dai H, Chen J and Gan X: Glutathione peroxidase 1 promotes NSCLC
resistance to cisplatin via ROS-induced activation of PI3K/AKT
pathway. Biomed Res Int. 2019:76405472019.PubMed/NCBI
|
|
34
|
Zhang Y, Zheng S, Zheng JS, Wong KH, Huang
Z, Ngai SM, Zheng W, Wong YS and Chen T: Synergistic induction of
apoptosis by methylseleninic acid and cisplatin, the role of
ROS-ERK/AKT-p53 pathway. Mol Pharm. 11:1282–1293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tonino SH, van Laar J, van Oers MH, Wang
JY, Eldering E and Kater AP: ROS-mediated upregulation of Noxa
overcomes chemoresistance in chronic lymphocytic leukemia.
Oncogene. 30:701–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiao DM, Yan L, Wang LS, Hu HZ, Tang XL,
Chen J, Wang J, Li Y and Chen QY: Exploration of inhibitory
mechanisms of curcumin in lung cancer metastasis using a
miRNA-transcription factor-target gene network. PLoS One.
12:e01724702017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X
and Wu MH: Luteolin inhibits tumorigenesis and induces apoptosis of
non-small cell lung cancer cells via regulation of MicroRNA-34a-5p.
Int J Mol Sci. 19:4472018. View Article : Google Scholar
|
|
38
|
Wang X, Dong K, Gao P, Long M, Lin F, Weng
Y, Ouyang Y, Ren J and Zhang H: MicroRNA-34a sensitizes lung cancer
cell lines to DDP treatment independent of p53 status. Cancer
Biother Radiopharm. 28:45–50. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Z, Kong Y, Yang W, Ma F, Zhang Y, Ji
S, Ma EM, Liu H, Chen Y and Hua Y: Upregulation of microRNA-34a
enhances the DDP sensitivity of gastric cancer cells by modulating
proliferation and apoptosis via targeting MET. Oncol Rep.
36:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu M, Hu J, Zhou B, Zhong Y, Lin N and Xu
R: TRIM29 prevents hepatocellular carcinoma progression by
inhibiting Wnt/β-catenin signaling pathway. Acta Biochim Biophys
Sin (Shanghai). 51:68–77. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song X, Fu C, Yang X, Sun D, Zhang X and
Zhang J: Tripartite motif-containing 29 as a novel biomarker in
non-small cell lung cancer. Oncol Lett. 10:2283–2288. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu C, Huang X, Hou S, Hu B and Li H:
Silencing of tripartite motif (TRIM) 29 inhibits proliferation and
invasion and increases chemosensitivity to cisplatin in human lung
squamous cancer NCI-H520 cells. Thorac Cancer. 6:31–37. 2015.
View Article : Google Scholar : PubMed/NCBI
|
